Bone densitometry competitors Lunar and Hologic are enjoying asurge in demand for their products thanks to Medicare reimbursementof dual-energy x-ray absorptiometry (DEXA). Unfortunately, theongoing legal battle between the arch-rivals is making it
Bone densitometry competitors Lunar and Hologic are enjoying asurge in demand for their products thanks to Medicare reimbursementof dual-energy x-ray absorptiometry (DEXA). Unfortunately, theongoing legal battle between the arch-rivals is making it difficultfor the companies to enjoy the fruits of their labors.
Both firms have posted quarterly financial results that showrevenues up. Income figures are less stellar, however, due tolegal costs incurred in patent litigation between the firms (SCAN9/14/94).
Lunar posted a 38% increase in revenues for its fourth quarter(end-June), to $12.8 million from $9.3 million in the fourth quarterof 1994. The Madison, WI, firm had annual revenues of $44.6 million,a 48% increase over $30 million in sales recorded in the 1994fiscal year.
Lunar's net income for the most recent quarter dropped 5%,to $1.6 million from $1.7 million in the corresponding perioda year ago. The company had a profit for the year of $6.7 million,up 15% from $5.8 million in fiscal 1994.
Hologic of Waltham, MA, recorded revenues of $11.3 millionfor its third quarter (end-June). That's up 3% compared to thethird quarter of 1994, when the firm had $10.9 million in sales.Year-to-date revenues stand at $30.5 million, up 7% compared tothe same period in 1994.
Hologic's net income for the third quarter was $487,668, down59% from the $1.2 million recorded in the same period a year ago.For the year to date, net income stands at $1.3 million, down48% from $2.5 million for the first nine months of 1994.
Chief executives from both companies attributed the lower profitsto the patent litigation, which includes several lawsuits relatingto bone measurement technology. Hologic said it spent $800,000on legal costs in the third quarter, while Lunar spent almostan equal amount, $766,000. The first trial date for the litigationhas been scheduled for Sept. 25.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.